Literature DB >> 27314074

STAT1-mediated translational control in tumor suppression and antitumor therapies.

Shuo Wang1, Antonis E Koromilas2.   

Abstract

Signal transducer and activator of transcription (STAT1) functions as a tumor suppressor but paradoxically protects tumor cells from death induced by DNA damaging drugs. An important mechanism employed by Stat1 to exert its tumor suppressor and cytoprotective effects involves translation of select mRNAs encoding proteins with either antitumor or prosurvival properties.

Entities:  

Keywords:  Antitumor therapies; STAT1; cell survival; chemotherapeutic drugs; gene transcription; mRNA translation initiation; protein phosphorylation

Year:  2015        PMID： 27314074      PMCID： PMC4909427          DOI： 10.1080/23723556.2015.1055049

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to antitumor drugs.

Authors:  Shuo Wang; Christos Patsis; Antonis E Koromilas
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

2.  The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation.

Authors:  Hsin-Sheng Yang; Aaron P Jansen; Anton A Komar; Xiaojing Zheng; William C Merrick; Sylvain Costes; Stephen J Lockett; Nahum Sonenberg; Nancy H Colburn
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

3.  Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.

Authors:  Huihui Ma; Caisheng Lu; Judith Ziegler; Ailing Liu; Antonia Sepulveda; Hideho Okada; Suzanne Lentzsch; Markus Y Mapara
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

Review 4.  Interferons and their stimulated genes in the tumor microenvironment.

Authors:  Hyeonjoo Cheon; Ernest C Borden; George R Stark
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

Review 5.  Targeting the translation machinery in cancer.

Authors:  Mamatha Bhat; Nathaniel Robichaud; Laura Hulea; Nahum Sonenberg; Jerry Pelletier; Ivan Topisirovic
Journal:  Nat Rev Drug Discov       Date:  2015-03-06       Impact factor: 84.694

6.  Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation.

Authors:  Jennifer F Raven; Virginie Williams; Shuo Wang; Michel L Tremblay; William J Muller; Joan E Durbin; Antonis E Koromilas
Journal:  Cell Cycle       Date:  2011-03-01       Impact factor: 4.534

Review 7.  The JAK-STAT pathway at twenty.

Authors:  George R Stark; James E Darnell
Journal:  Immunity       Date:  2012-04-20       Impact factor: 31.745

Review 8.  Immunogenic cell death in cancer therapy.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Oliver Kepp; Laurence Zitvogel
Journal:  Annu Rev Immunol       Date:  2012-11-12       Impact factor: 28.527

Review 9.  The tumor suppressor function of STAT1 in breast cancer.

Authors:  Antonis E Koromilas; Veronika Sexl
Journal:  JAKSTAT       Date:  2013-04-01

10.  Stat1 phosphorylation determines Ras oncogenicity by regulating p27 kip1.

Authors:  Shuo Wang; Jennifer F Raven; Joan E Durbin; Antonis E Koromilas
Journal:  PLoS One       Date:  2008-10-22       Impact factor: 3.240
  10 in total
  2 in total

1.  Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2.

Authors:  Yuan Chen; Lei Fang; Jiali Zhang; Gefei Li; Mengni Ma; Changxi Li; Jianxin Lyu; Qing H Meng
Journal:  Int J Mol Sci       Date:  2017-03-09       Impact factor: 5.923

2.  Synergistic inhibition of colon cancer growth by the combination of methylglyoxal and silencing of glyoxalase I mediated by the STAT1 pathway.

Authors:  Yuan Chen; Lei Fang; Gefei Li; Jiali Zhang; Changxi Li; Mengni Ma; Chen Guan; Fumao Bai; Jianxin Lyu; Qing H Meng
Journal:  Oncotarget       Date:  2017-06-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.